BPXA Stock Overview
Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Bellicum Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.06 |
| 52 Week High | €0.06 |
| 52 Week Low | €0.06 |
| Beta | 1.38 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| BPXA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.5% | 0.8% |
| 1Y | n/a | -18.9% | 2.0% |
Return vs Industry: Insufficient data to determine how BPXA performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how BPXA performed against the German Market.
Price Volatility
| BPXA volatility | |
|---|---|
| BPXA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: BPXA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BPXA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 13 | Dave Maggio | www.bellicum.com |
Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company’s clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen.
Bellicum Pharmaceuticals, Inc. Fundamentals Summary
| BPXA fundamental statistics | |
|---|---|
| Market cap | €772.38k |
| Earnings (TTM) | -€21.01m |
| Revenue (TTM) | €1.42m |
0.5x
P/S Ratio0.0x
P/E RatioIs BPXA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BPXA income statement (TTM) | |
|---|---|
| Revenue | US$1.51m |
| Cost of Revenue | US$18.63m |
| Gross Profit | -US$17.12m |
| Other Expenses | US$5.26m |
| Earnings | -US$22.38m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.84 |
| Gross Margin | -1,135.08% |
| Net Profit Margin | -1,483.95% |
| Debt/Equity Ratio | 0% |
How did BPXA perform over the long term?
See historical performance and comparison